Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma

BACKGROUND: The FOLFIRINOX regimen is the standard first-line treatment for advanced pancreatic adenocarcinoma (aPDAC). However, because of its potential toxicity, predictive biomarkers could help clinical decision-making. METHODS: A cohort of 97 aPDAC patients treated with first-line FOLFIRINOX wer...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Aarnink, Anne, Richard, Corentin, Truntzer, Caroline, Vincent, Julie, Bengrine, Leila, Vienot, Angélique, Borg, Christophe, Ghiringhelli, Francois
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5986639/
https://ncbi.nlm.nih.gov/pubmed/29876012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25424
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares